Introduction

This episode we have the pleasure of sitting down with Dr. Hillary de Brock to discuss two foundational articles on pulmonary arterial hypertension treatment. We will discuss the 2013 serifin and 2015 ambition trials both of which were published in the New England Journal of Medicine. These studies ultimately led to the approval of rheosiguat for PAH and inoperable or residual CTAF.